Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of enobosarm in advanced androgen receptor-positive triple-negative breast cancer
2014-004989-23Phase 2Completed
- Sponsor
- GTx
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enobosarm in triple-negative breast cancer (TNBC) and breast cancer, sponsored by GTx. Primary endpoint: Clinical benefit rate at 16 weeks in centrally confirmed AR-positive TNBC. Started May 2015; status: completed.
02
Drugs
enobosarm
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2014-004989-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004989-23.